3226 J ournal of Medicinal Chemistry, 1999, Vol. 42, No. 17
Hoffman et al.
(12) Minor, D. L.; Wyrick, S. D.; Charifson, P. S.; Watts, V. J .; Nichols,
D. E.; Mailman, R. B. Synthesis and molecular modeling of
1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-
tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine an-
tagonists. J . Med. Chem. 1994, 37, 4317-4328.
(13) Mailman, R. B.; Nichols, D. E.; Tropsha, A. Molecular Drug
Design and Dopamine Receptors. In Dopamine Receptors, Neve,
K., Neve, R., Eds.; Humana Press: Totowa, NJ , 1996; pp 105-
133.
(14) Allen, F. H.; Davies, J . E.; Galloy, J . J .; J ohnson, O.; Kennard,
O.; Macrae, C. F.; Mitchell, E. M.; Mitchell, G. F.; Smith, J . M.;
Watson, D. G. The development of versions 3 and 4 of the
Cambridge Structural Database System. J . Chem. Inf. Comput.
Sci. 1991, 31, 187-204.
(15) Allen, F. H.; Bellard, S.; Brice, M. D.; Cartwright, B. A.;
Doubleday, A.; Higgs, H.; Hummelink, T.; Hummelink-Peters,
B. G.; Kennard, O.; Motherwell, W. D. S.; Rodgers, J . R.; Watson,
D. G. The Cambridge Crystal Data Centre: computer-based
search, retrieval, analysis, and display of information. Acta-
Crystallogr. Sect B: Struct. Crystallogr. Cryst. Chem. 1979, B35,
2331-2339.
(35) Hansen, P. J .; J urs, P. C. Chemical Applications of Graph Theory
II: Isomer Enumeration. J . Chem. Educ. 1988, 65, 574.
(36) Kubinyi, H. Variable Selection in QSAR Studies. I. An Evolu-
tionary Algorithm. Quant. Struct.-Act. Relat. 1994, 13, 285-294.
(37) Sutter, J . M.; Dixon, S. L.; J urs, P. C. Automated Descriptor
Selection for Quantitative Structure-Activity Relationships
Using Generalized Simulated Annealing. J . Chem. Inf. Comput.
Sci. 1995, 35, 77-84.
(38) Fogel, D. B. Applying Evolutionary Programming to Selected
Traveling Salesman Problems. Cybern. Syst. (USA) 1993, 24,
27-36.
(39) Fogel, D. B.; Fogel, L. J .; Porto, V. W. Evolutionary Methods for
Training Neural Networks; IEEE Conference on Neural Net-
works for Ocean Engineering (Catal. No. 91CH3064-3); IEEE,
1991; pp 317-327.
(40) Goldberg, D. E. Genetic Algorithm in Search, Optimization, and
Machine Learning; Addison-Wesley: Reading, MA, 1989.
(41) Forrest, S. Genetic Algorithms: Principles of Natural Selection
Applied to Computation. Science 1993, 261, 872-878.
(42) Bohachevsky, I. O.; J ohnson, M. E.; Stein, M. L. Generalized
Simulated Annealing for Function Optimization. Technometrics
1986, 28, 209-217.
(43) Kalivas, J . H., Generalized Simulated Annealing for Calibration
Sample Selection from an Existing Set and Orthoginization of
Undesigned Experiments. J . Chemomet. 1991, 5, 37-48.
(44) Iorio, L. C.; Barnett, A.; Leitz, F. H.; Houser, V. P.; Korduba, C.
A. SCH23390, a potential benzazepine antipsychotic with unique
interactions on dopaminergic systems. J . Pharmacol. Exp. Ther.
1983, 226, 462-468.
(45) Iorio, L. C.; Barnett, A.; Billard, W.; Gold, E. H. Benzazepines:
structure-activity relationships between D1 receptor blockade
and selected pharmacological effects. In Neurobiology of Central
D1-Dopamine Receptors; Creese, I., Breese, G. R., Eds.; Plenum
Press: New York, 1986; pp 1-14.
(46) Tice, M. A.; Hashemi, T.; Taylor, L. A.; Duffy, R. A.; McQuade,
R. D. Characterization of the binding of SCH39166 to the five
cloned dopamine receptor subtypes. Pharmacol. Biochem. Behav.
1994, 49, 567-571.
(47) Ghosh, D.; Snyder, S. E.; Watts, V. J .; Mailman, R. B.; Nichols,
D. E. 8,9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]iso-
quinoline: a potent full dopamine D1 agonist containing a rigid
â-phenyl dopamine pharmacophore. J . Med. Chem. 1996, 39,
549-555.
(48) Sybyl User’s Manual Version 6.2; Tripos, Inc.: St. Louis, MO,
1995.
(49) Miller, D. D. Steric aspects of dopaminergic drugs. Fed. Proc.
1978, 37, 2392-2395.
(50) Strange, P. G. The binding of agonists and antagonists to
dopamine receptors. Biochem. Soc. Trans. 1996, 24, 188-192.
(51) Berger, J . G.; Chang, W. K.; Clader, J . W.; Hou, D.; Chipkin, R.
E.; McPhail, A. T. Synthesis and receptor affinities of some
conformationally restricted analogues of the dopamine D1 selec-
tive ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-
1H-3-benzazepin-7-ol. J . Med. Chem. 1989, 32, 1913-1921.
(52) Shah, J . H.; Kline, R. H.; Geter-Douglass, B.; Izenwasser, S.;
Witkin, J . M.; Newman, A. H. (()-3-[4′-(N,N-dimethylamino)-
cinnamyl]benzazepine analogues: novel dopamine D1 receptor
antagonists. J . Med. Chem. 1996, 39, 3423-3428.
(53) Pettersson, I.; Gundertofte, K.; Palm, J .; Liljefors, T. A study
on the contribution of the 1-phenyl substituent to the molecular
electrostatic potentials of some benzazepines in relation to
selective dopamine D-1 receptor activity. J . Med. Chem. 1992,
35, 502-507.
(16) Rusinko, A., III; Skell, J . M.; Balducci, R.; McGarity, C. M.;
Pearlman, R. S. Concord, A Program for the Rapid Generation
of High Quality Approximate 3-Dimensional Molecular Struc-
tures; The University of Texas at Austin and Tripos Associates:
St. Louis, MO, 1988.
(17) Pearlman, R. S. Rapid generation of high quality approximate
3D molecular structures. Chem. Des. Aut. News 1987, 2, 1-6.
(18) Marshall, G. R.; Barry, C. D.; Bosshard, H. E.; Dammkoehler,
R. A.; Dunn, D. A. The Conformational Parameter in Drug
Design: the Active Analogue Approach. In Computer-Assisted
Drug Design; Olson, E. C., Christoffersen, R. E., Eds.; American
Chemical Society, Washington, DC, 1979; Vol. 112, pp 205-226.
(19) Marshall, G. R.; Cramer, R. D., III. Three-Dimensional Structure-
Activity Relationships. TIPS Rev. 1988, 9, 285-289.
(20) Simon, Z.; Badileuscu, I.; Racovitan, T. Mapping of dihydrofolate-
reductase receptor site by correlation with minimal topological
(steric) differences. J . Theor. Biol. 1977, 66, 485-495.
(21) Rhyu, K. B.; Patel, H. C.; Hopfinger, A. J . A 3D-QSAR Study of
Anticoccidial Triazines using molecular shape analysis J . Chem.
Inf. Comput. Sci. 1995, 35, 771-778.
(22) Cramer, R. D., III; Patterson, D. E.; Bunce, J . D. Comparative
Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding
of Steroids to Carrier Proteins. J . Am. Chem. Soc. 1988, 110,
5959-5967.
(23) Klebe, G.; Abraham, U.; Mietzner, T. Molecular Similarity
Indices in a Comparative Analysis (CoMSIA) of Drug Molecules
to Correlate and Predict Their Biological Activity. J . Med. Chem.
1994, 37, 4130-4146.
(24) Kubinyi, H.; Folkers, G.; Martyn, Y. 3D QSAR in Drug Design;
Kluwer/ESCOM: Leiden, 1998; Vol. 2-3.
(25) Camilleri, P.; Livingstone, D. J .; Murphy, J . A.; Manallack, D.
T. Chiral Chromatography and Multivariate Quantitative Struc-
ture-Property Relationships of Benzimidazole Sulphoxides. J .
Comput.-Aided Mol. Des. 1993, 7, 61-69.
(26) Geladi, P.; Kowalski, B. R. Partial Least Squares Regression:
A Tutorial. Anal. Chim. Acta 1986, 185, 1-17.
(27) J ansson, P. A. Neural Networks: An Overview. Anal. Chem.
1991, 63, 357A-362A.
(28) So, S. S.; Richards, W. G. Application of Neural Networks:
Quantitative Structure-Activity Relationships of the Deriva-
tives of 2,4-Diamino-5-(substituted-benzyl)pyrimidines as DHFR
Inhibitors. J . Med. Chem. 1992, 35, 3201-3207.
(29) Cramer, R. D., III; DePriest, S. A.; Patterson, D. E.; Hecht, P.
The Developing Practice of Comparative Molecular Field Analy-
sis. In 3D QSAR in Drug Design: Theory, Methods, and
Applications; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 443-
485.
(30) Cho, S. J .; Tropsha, A.; Suffness, M.; Cheng, Y. C.; Lee, K. H.
Antitumor Agents. 163. Three-Dimensional Quantitative Struc-
ture-Activity Relationship Study of 4′-O-Demethylpipodophyl-
lotoxin Analogues Using the Modified CoMFA/q2-GRS Approach.
J . Med. Chem. 1996, 39, 1383-1395.
(31) Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-
Dimensional QSAR of Human Immunodeficiency Virus (I)
Protease Inhibitors. 1. A CoMFA Study Employing Experimen-
tally-Determined Alignment Rules. J . Med. Chem. 1993, 36,
4152-4160.
(54) Pettersson, I.; Liljefors, T.; Bogeso, K. Conformational analysis
and structure-activity relationships of selective dopamine D-1
receptor agonists and antagonists of the benzazepine series. J .
Med. Chem. 1990, 33, 2197-2204.
(55) Tropsha, A.; Cho, S. J . Cross-Validated R2 Guided Region
Selection for CoMFA Studies. In Kubinyi, H., Folkers, G.,
Martin, Y. C., Eds.; 3D QSAR in Drug Design; Kluwer Academic
Publishers: Dordrecht, The Netherlands, 1998; Vol. III, pp 57-
69.
(56) MOLCONN-X version 2.0, Hall Associates Consulting: Quincy,
MA.
(57) Iorio, L. C.; Barnett, A.; Billard, W.; Gold, E. H. Benzazepines:
structure-activity relationships between D1 receptor blockade
and selected pharmacological effects. Adv. Exp. Med. Biol. 1986,
204, 1-14.
(58) Shah, J . H.; Izenwasser, S.; Geter-Douglass, B.; Witkin, J . M.;
Newman, A. H. (()-(N-alkylamino)benzazepine analogues: novel
dopamine D1 receptor antagonists. J . Med. Chem. 1995, 38,
4284-4293.
(32) Cho, S. J .; Garsia, M. L. S.; Bier, J .; Tropsha, A. Structure Based
Alignment and Comparative Molecular Field Analysis of Acetyl-
cholinesterase Inhibitors. J . Med. Chem. 1996, 39, 5064-5071.
(33) Rogers, D.; Hopfinger, A. J . Application of Genetic Function
Approximation to Quantitative Structure-Activity Relationships
and Quantitative Structure-Property Relationships. J . Chem.
Inf. Comput. Sci. 1994, 34, 854-866.
(34) Trinajstic, N. Chemical Graph Theory; CRC Press: Boca Raton,
FL, 1983; Vol. I, II.
J M980415J